1. Serious Adverse Events With Infliximab: Analysis of Spontaneously Reported Adverse Events 
Richard A. Hansen, Gerald Gartlehner, Gregory E. Powell, Robert S. Sandler 
Clinical Gastroenterology and Hepatology 
Volume 5, Issue 6, Pages e1 (June 2007)
DOI: /j.cgh
Copyright © 2007 AGA Institute Terms and Conditions

2. Figure 1
Cumulative EBGM for select adverse events. *The signal threshold (EB05 ≥ 2) is represented by the lower bound of the 90% CI.
Clinical Gastroenterology and Hepatology 2007 5, e1DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

3. Figure 2
Cumulative EGBM for granulomatous and non-granulomatous infections. *The signal threshold (EB05 ≥ 2) is represented by the lower bound of the 90% CI.
Clinical Gastroenterology and Hepatology 2007 5, e1DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

4. Figure 3
Cumulative EGBM for infections by pathogen type. *The signal threshold (EB05 ≥ 2) is represented by the lower bound of the 90% CI.
Clinical Gastroenterology and Hepatology 2007 5, e1DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions